文献速递肿瘤 PET/CT核素与放射性配体治疗

神经内分泌肿瘤患者中[18F]FET-βAG-TOCA PET/CT与[68Ga]Ga-DOTA-肽PET/CT的生长抑素受体显像:一项前瞻性2期对比研究

Somatostatin Receptor Imaging with [18F]FET-βAG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study.
PubMed 文献 · J Nucl Med · 2024-02-08

本前瞻性2期非劣效研究纳入45例组织学确诊的1-2级神经内分泌肿瘤患者,在6个月窗口内(中位77天,范围6-180天)先后行[18F]FET-βAG-TOCA与[68Ga]Ga-DOTA-肽PET/CT。两种显像剂共检出285个病灶,[18F]FET-βAG-TOCA在8例患者中额外发现13个肿瘤沉积,[68Ga]Ga-DOTA-肽在5例患者中额外发现7个病灶。结论认为[18F]FET-βAG-TOCA在显示神经内分泌肿瘤方面不劣于[68Ga]Ga-DOTA-肽。

要点

  • 45例1-2级神经内分泌肿瘤患者行两种生长抑素受体PET/CT对比显像。
  • 两种显像剂共检出285个病灶,SUVmax高度相关(r=0.91;P<0.001)。
  • 肝脏肿瘤-本底比[18F]FET-βAG-TOCA显著低于[68Ga]Ga-DOTA-肽(2.5±1.9 vs 3.5±2.3;P<0.001)。

核心结论

  • [18F]FET-βAG-TOCA在显示神经内分泌肿瘤方面不劣于[68Ga]Ga-DOTA-肽。
  • 鉴于回旋加速器生产的氟放射性同位素半衰期更长且可及性好,[18F]FET-βAG-TOCA可考虑用于常规临床实践。

研究设计与样本

  • 前瞻性2期非劣效对比研究。
  • 纳入45例组织学确诊的1级和2级神经内分泌肿瘤患者。
  • 两种PET/CT在6个月窗口内完成(中位77天;范围6-180天)。
  • 注射165 MBq [18F]FET-βAG-TOCA后50分钟行全身PET/CT。
  • 由2名非盲经验阅片者比较病灶和区域水平的SUVmax及肿瘤-本底比,另由3名经验阅片者随机盲法阅片并在区域水平评估一致性。

主要发现

  • 两种显像方式共检出285个病灶。
  • [18F]FET-βAG-TOCA PET/CT在8例患者中额外发现13个肿瘤沉积。
  • [68Ga]Ga-DOTA-肽PET/CT在5例患者中额外发现7个病灶。
  • 两种显像剂SUVmax高度相关(r=0.91;P<0.001)。
  • 除肝脏外,各区域中位SUVmax无差异;肝脏中[18F]FET-βAG-TOCA的中位肿瘤-本底比显著低于[68Ga]Ga-DOTA-肽(2.5±1.9 vs 3.5±2.3;P<0.001)。

临床怎么用

  • 作者认为,鉴于氟放射性同位素半衰期更长且可及性好,[18F]FET-βAG-TOCA可考虑用于常规临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a clinical need for 18F-labeled somatostatin analogs for the imaging of neuroendocrine tumors (NET), given the limitations of using [68Ga]Ga-DOTA-peptides, particularly with regard to widespread accessibility. We have shown that [18F]fluoroethyl-triazole-[Tyr3]-octreotate ([18F]FET-βAG-TOCA) has favorable dosimetry and biodistribution. As a step toward clinical implementation, we conducted a prospective, noninferiority study of [18F]FET-βAG-TOCA PET/CT compared with [68Ga]Ga-DOTA- peptide PET/CT in patients with NET. Methods: Forty-five patients with histologically confirmed NET, grades 1 and 2, underwent PET/CT imaging with both [18F]FET-βAG-TOCA and [68Ga]Ga-peptide performed within a 6-mo window (median, 77 d; range, 6-180 d). Whole-body PET/CT was conducted 50 min after injection of 165 MBq of [18F]FET-βAG-TOCA. Tracer uptake was evaluated by comparing SUVmax and tumor-to-background ratios at both lesion and regional levels by 2 unblinded, experienced readers. A randomized, blinded reading of both scans was also then undertaken by 3 experienced readers, and consensus was assessed at a regional level. The ability of both tracers to visualize liver metastases was also assessed. Results: A total of 285 lesions were detected on both imaging modalities. An additional 13 tumor deposits were seen in 8 patients on [18F]FET-βAG-TOCA PET/CT, and [68Ga]Ga-DOTA-peptide PET/CT detected an additional 7 lesions in 5 patients. Excellent correlation in SUVmax was observed between both tracers (r = 0.91; P < 0.001). No difference was observed between median SUVmax across regions, except in the liver, where the median tumor-to-background ratio of [18F]FET-βAG-TOCA was significantly lower than that of [68Ga]Ga-DOTA-peptide (2.5 ± 1.9 vs. 3.5 ± 2.3; P < 0.001). Conclusion: [18F]FET-βAG-TOCA was not inferior to [68Ga]Ga-DOTA-peptide in visualizing NET and may be considered in routine clinical practice given the longer half-life and availability of the cyclotron-produced fluorine radioisotope.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dubash S, Barwick TD, Kozlowski K, et al. Somatostatin Receptor Imaging with [18F]FET-βAG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study. J Nucl Med. 2024. PMID: 38331457. doi:10.2967/jnumed.123.266601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。